• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-3/A filed by IceCure Medical Ltd.

    3/16/26 4:01:25 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    F-3/A 1 ea0281893-f3a1_icecure.htm AMENDMENT NO. 1 TO FORM F-3

    As filed with the Securities and Exchange Commission on March 16, 2026

    Registration No. 333-290046

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Amendment No. 1

    to 

    FORM F-3

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    IceCure Medical Ltd.

    (Exact name of registrant as specified in its charter)

     

    Not Applicable

    (Translation of Registrant’s Name into English)

     

    Israel   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

      (I.R.S. Employer
    Identification No.)

     

    7 Ha’Eshel St., PO Box 3163
    Caesarea, 3079504 Israel

    Tel: +972.4623.0333

    (Address and telephone number of registrant’s principal executive offices)

     

    IceCure Medical Inc.

    10 W Prospect Street, Suite 401

    Nanuet, New York 10954

    Tel: +1.888.902.5716

    (Name, address, and telephone number of agent for service)

     

    Copies to:

     

    Oded Har-Even, Esq.

    Eric Victorson, Esq.

    Ilana Neck Levin, Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    Tel: 212.660.3000

     

    Reut Alfiah, Adv.

    Gal Cohen, Adv.

    Sullivan & Worcester Tel Aviv
    (Har-Even & Co.)

    28 HaArba’a St. HaArba’a Towers,
    North Tower, 35th Floor

    Tel Aviv, Israel 6473925
    Tel: +972.74.758.0480

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date hereof.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ 

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

     

    Emerging growth company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. 

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    IceCure Medical Ltd., or the Company, is filing this Amendment No. 1, or this Amendment No. 1, to the Registration Statement on Form F-3 (File No. 333-290046) originally filed on September 4, 2025, or the Registration Statement, solely for the purpose of updating the consent of Brightman Almagor Zohar & Co., a firm in the Deloitte global network, independent registered public accounting firm for the Company, filed as Exhibit 23.1 to the Registration Statement.

     

    Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Registration Statement nor does this Amendment No. 1 reflect any events that have occurred after the Registration Statement was filed.

     

     

     

     

    Item 9. Exhibits

     

    Exhibit
    Number
      Description of Document
    1.1***   Form of Underwriting Agreement.
    3.1   Amended and Restated Articles of Association of IceCure Medical Ltd. (incorporated herein by reference to Exhibit 99.1 to our Report of Foreign Private Issuer (File No. 001-40753) filed with the SEC on January 8, 2026).
    4.1***   Form of Warrant.
    4.2***   Form of Unit Agreement.
    5.1**   Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.), Israeli counsel to IceCure Medical Ltd.
    5.2***    Opinion of Sullivan & Worcester LLP, U.S. counsel to IceCure Medical Ltd.
    23.1*   Consent of Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, independent registered public accounting firm.
    23.2**   Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in Exhibit 5.1).
    23.3***    Consent of Sullivan & Worcester LLP (included in Exhibit 5.2).
    24.1**   Power of Attorney (included on signature page).
    107**   Calculation of Filing Fee Tables.

     

    * Filed herewith.
    ** Previously filed. 
    *** To be filed, if applicable, by post-effective amendment or incorporated by reference in connection with the offering of any securities, as appropriate.

     

    1

     

     

    Item 10. Undertakings

     

    (a) The undersigned Registrant hereby undertakes:

     

      1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and a(l)(iii) do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

      (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

      (4) To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.

      

    2

     

     

      (5) That, for the purpose of determining liability under the Securities Act to any purchaser:

     

      (i) If the Registrant is relying on Rule 430B:

     

      A. Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

      B. Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

     

      (ii) If the Registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

     

      (6) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell securities to such purchaser:

      

      (i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

     

      (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

     

    3

     

     

      (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and

     

      (iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

      

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.

     

    (d) The undersigned Registrant hereby undertakes that:

     

      (1) for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.

     

      (2) for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

      

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement on Form F-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in Caesarea, Israel, on March 16, 2026.

     

      ICECURE MEDICAL LTD.
         
      By: /s/ Ronen Tsimerman
        Ronen Tsimerman
        Chief Financial Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form F-3 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Eyal Shamir   Chief Executive Officer, Director   March 16, 2026
    Eyal Shamir   (Principal Executive Officer)    
             
    /s/ Ronen Tsimerman   Chief Financial Officer   March 16, 2026
    Ronen Tsimerman   (Principal Financial and Accounting Officer)    
             
    *   Director, Chairman of the Board of Directors   March 16, 2026
    Ron Mayron        
             
    *   Director   March 16, 2026
    Vincent Chun Hung Chan        
             
    *   Director   March 16, 2026
    Yang Huang        
             
    *   Director   March 16, 2026
    Sharon Levita        
             
        Director   March 16, 2026
    Li Haixiang         
             
     *   Director   March 16, 2026
    Yonatan Malca        

     

    *By /s/ Eyal Shamir  
      /s/ Eyal Shamir  
      Attorney-in-Fact  

     

    5

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, IceCure Medical Inc., the duly authorized representative in the United States of IceCure Medical Ltd., has signed this registration statement on March 16, 2026. 

     

      /s/ IceCure Medical Inc.
      IceCure Medical Inc.

     

    6

     

    Get the next $ICCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

    IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense®Clinical study sites may offer ProSense® cryoablation to additional patients not enrolled in the study, supporting its potential broader commercial adoptionPost-market study will be conducted using cryoprobes sold exclusively by IceCure and facilities will be able to use CPT Category III reimbursement codeCAESAREA, Israel, March 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surg

    3/11/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Icecure Medical with a new price target

    Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

    2/2/22 11:13:08 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners initiated coverage on Icecure Medical with a new price target

    Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

    9/22/21 8:10:09 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    SEC Filings

    View All

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    3/17/26 9:03:37 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by IceCure Medical Ltd.

    20-F - IceCure Medical Ltd. (0001584371) (Filer)

    3/17/26 8:44:49 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form F-3/A filed by IceCure Medical Ltd.

    F-3/A - IceCure Medical Ltd. (0001584371) (Filer)

    3/16/26 4:01:25 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Financials

    Live finance-specific insights

    View All

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

    Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer Demand for ProSense® systems expected to accelerate in 2026 Total U.S. population of approximately 200,000 patients, includes women aged 70+, those not suitable for surgery and benign breast tumors  Conference call to be held today, November 19, 2025 at 10:00 am Eastern Time CAESAREA, Israel, Nov. 19, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal

    11/19/25 8:54:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

    Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

    8/28/23 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

    Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

    12/6/22 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    2/14/23 8:46:31 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    1/24/23 5:04:22 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care